Machine signal
Active cluster sell — 5 distinct insiders, $126.5M, window ends Sep 8, 2026.
Figures computed from official regulatory filings — .
Analysttarget 27.58 USD (+45%) · consensus 4.77/5 · 13 buy · 0 hold · 0 sell
Ownershipinsiders 1.61% · institutions 110.83% · short 23.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Relay Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
5 buys270 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Bergstrom Donald A | Sell | $161.8K | SEC |
| Patel Sanjiv | Sell | $912.9K | SEC |
| Catinazzo Thomas | Sell | $335.6K | SEC |
| SVF Pauling (Cayman) Ltd | Sell | $116.4M | SEC |
| Rahmer Peter | Sell | $90.3K | SEC |
| Catinazzo Thomas | Sell | $349.7K | SEC |
| Patel Sanjiv | Sell | $979.9K | Unusual size | SEC |
| Rahmer Peter | Sell | $13.9K | SEC |
| Bergstrom Donald A | Sell | $41.6K | SEC |
| Catinazzo Thomas | Sell | $27.2K | SEC |
| Catinazzo Thomas | Sell | $331.1K | SEC |
| Patel Sanjiv | Sell | $943.7K | Unusual size | SEC |
| Patel Sanjiv | Award | $21.2K | Unusual size | SEC |
| Bergstrom Donald A | Sell | $162K | SEC |
| Rahmer Peter | Award | $21.2K | Unusual size | SEC |
| Rahmer Peter | Sell | $954.5K | Unusual size | SEC |
| Catinazzo Thomas | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Catinazzo Thomas | Exercise | $283.9K | Unusual size | SEC |
| Catinazzo Thomas | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Catinazzo Thomas | Sell | $1M | Unusual size | SEC |
| Catinazzo Thomas | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bergstrom Donald A | Exercise | $385K | Unusual size | SEC |
| Catinazzo Thomas | Sell | $955.8K | Unusual size | SEC |
| Catinazzo Thomas | Sell | $301.4K | Unusual size | SEC |
| Catinazzo Thomas | Sell | $875K | Unusual size | SEC |